Page 4 - Pharma Stocks

Jagsonpal Pharma rallies 19% on open offer by Infinity Holdings Group

Infinity Holdings Group made an open offer to buy 26 per cent stake in the company at a price of Rs 235 per share

Lab stocks scramble for new growth in India as Covid gains halve

Surging healthcare spending and demand for Covid tests led to multifold share-price gains for pathology firms globally during the pandemic

Two Cipla promoters sell 20 mn shares; promoter group now holds 34.23%

Chairman Y K Hamied and Vice Chairman MK Hamied, who are non-executive directors and promoters, have sold 2,01,69,756 shares on Tuesday

Biocon gains 3%, at 6-month high in a weak market; stock up 18% in 3 weeks

Biocon said its subsidiary Biocon Pharma has received approval of its ANDA for Posaconazole Delayed-Release tablets from the US FDA.

Torrent Pharma tumbles 14% on disappointing Q3 results

In Q3FY22, earnings before interest tax and depreciation and amortization (EBITDA) margins declined 490 bps YoY to 25.5 per cent driven by price erosion in the US.

Aurobindo Pharma down 5% on USFDA warning letter for Hyderabad unit

The company believes that this will not impact the existing business from this facility.

Sun Pharma gains 4% on earnings optimism, stock scales a 5-year high

The better traction in the specialty segment and improvement in domestic business to drive the margin expansion in Q3.

Stocks to Watch: RIL, Wockhardt, IDBI Bk, SJVN, Titan, DMart, FMCG, Pharma

Pharma shares may be in focus as India's apex health research organization ICMR has raised concerns around the safety for use of the oral antiviral drug Molnupiravir

Stocks to Watch: RIL, Airtel, HUL, SBI, DB Realty, pharma, steel, textiles

Reliance Jio plans its biggest ever rupee bond sale, while Bharti Airtel shelves its plans to de-merge its core telecom business

Pharma shares trade firm; Laurus up 2%, Sun Pharma nears 52-week high

Sun Pharma, Cipla, Natco, Dr Reddy's, Torrent Pharma, Aurobindo Pharma and Strides have launched a generic version of Molnupiravir in India post approval for emergency use authorisation from DCGI

Stocks to Watch: Textiles, Amara Raja, Airtel, TCS, ITC, Ajanta Pharma

Textiles shares shall be in limelight as the government has released the operational guidelines for the production-linked incentive (PLI) scheme

Ajanta Pharma gains 5% on share buyback plan, board to meet on Dec 28

The board of directors of the company is scheduled to consider a proposal for buy-back of equity shares on Tuesday, December 28.

Eris Lifesciences soars 10% on JV with MJ Biopharm to enter insulin segment

The purpose of entering into the agreement is expansion of product portfolio to offer biotherapeutic options to the patients in cardio-metabolic segment, Eris said in statement

Unichem Labs surges 15% on ANDA nod from USFDA for Aripiprazole tablets

Aripiprazole tablets are indicated for Schizophrenia and Irritability associated with Autistic Disorder

Glenmark, Alembic, Cipla: Pharma stocks on a booster dose this December

Select pharma stocks look good on the technical charts and may jump up to 15 per cent in December. On the fundamental side, fears of Omicron variant spreading may also keep them in news and buzzing

Stocks to Watch: Reliance, ITC, Paytm, BoB, FMCG, pharma, airline stocks

FMCG stocks are likely to be in focus on the back of price hike announced, while airline shares too may be on investor's radar following the fresh world-wide Coivd-19 scare

Brokerages are betting on pharma stocks with India focus: Analysts

While domestic growth is pegged at double digits, recovery in the US may take a couple of quarters

Pharma stocks rally on buzz about new Covid variant, travel stocks sink

Huge gains for Cipla, Alkem Labs and Dr Lal Path, even as IndiGo, Chalet Hotels and IHC tank

Market wrap: Sensex sinks 1,688 pts, Nifty holds 17K; Rs 7.5-trn investor wealth lost

Pharma stocks soar as investors turn to defensive bets; dollar index inches towards 97 mark

BSE Healthcare index up 2%; Cipla, Alkem, Dr.Reddy's rally up to 8%

The pharma index had taken a breather over the past three months after displaying relative out-performance during CY20-21.